En Es
Categories

Industry News

Roche Launches Digital Pathology Image Analysis Algorithms for Precision Patient Diagnosis in Breast Cancer

By Labmedica International staff writers
13 Jan 2021

Image: uPath HER2 Dual ISH image analysis for breast cancer (Photo courtesy of Roche)Roche (Basel, Switzerland) has announced the CE-IVD launch of its automated digital pathology algorithms, uPath HER2 (4B5) image analysis and uPath Dual ISH image analysis for breast cancer to help determine the best treatment strategy for each patient.

The image analysis algorithms use artificial intelligence (AI) to support pathologists in making faster, more accurate patient diagnoses in breast cancer. A mutation in the HER2 gene, which occurs in as many as 20% of the 2.1 million cases of breast cancer diagnosed globally each year, is responsible for aggressive growth in some patients. Identifying this mutation is important in determining which patients may benefit from targeted treatment. uPath HER2 (4B5) image analysis for breast cancer helps pathologists to quickly determine whether tumors are positive for the HER2 biomarker, highlighting positively stained tumor cell membranes with a clear visual overlay for easy reference.

uPath HER2 Dual ISH image analysis for breast cancer assists the pathologist in the determination of HER2 gene amplification. A heatmap is provided to guide pathologists to areas of interest where the algorithm can identify cells to inform the determination of a treatment strategy. Validated on the VENTANA HER2 (4B5) assay and the VENTANA HER2 Dual ISH DNA Probe Cocktail, the algorithms are ready-to-use and integrated within the Roche uPath enterprise software.

The uPath HER2 (4B5) image analysis and uPath HER2 Dual ISH image analysis algorithms for breast cancer expand Roche’s digital pathology portfolio to empower precision diagnosis. The uPath image analysis algorithm suite for pathology decision support offers ready-to-use image analysis tools, providing fast, consistent and automated analysis so that pathologists can quickly, accurately and confidently assess immunohistochemistry and in situ hybridization. All algorithms in the suite for uPath software will provide image analysis of VENTANA DP 200 scanned slide images stained with a Roche Tissue Diagnostics assay.

“About 15 to 20% of women diagnosed with breast cancer are HER2 positive, which makes fast and accurate diagnosis critical,” said Thomas Schinecker, CEO Roche Diagnostics. “Roche is continuing to innovate in HER2 diagnostics by providing precise information through image analysis algorithms for pathology decision support.”






E-mail Print
FaceBook Twitter Google+ Linked in

Roche Diagnostics

Develops, manufactures, and markets a wide range of in vitro diagnostic systems, instruments, reagents, and tests
More info

More articles about Roche Diagnostics

28 Mar 2022
Roche and BMS Collaborate on Digital Pathology Algorithms and Cancer Diagnostic Assays
Advances in computation and artificial intelligence (AI) in digital pathology are showing promise to meet the demand for more accurate and comprehensive assessment of pathology results to enable improved patient outcomes. Roche (Basel, Switzerland; www.roche.com) has entered into a collaboration with Bristol Myers Squibb (BMY, New York, NY, USA) to support the advancement of two assays for use in clinical trials with the development and deployment of two new digital pathology algorithms.
Read More
02 Dec 2021
Roche Completes Acquisition of TIB Molbiol Group
Roche (Basel, Switzerland) has completed its share purchase agreement to acquire 100% of the outstanding shares of TIB Molbiol Group (Berlin, Germany).
Read More
16 Mar 2021
Roche to Acquire Genmark Diagnostics to Access Novel Technology to Test for Pathogens with One Patient Sample
Roche (Basel, Switzerland) and GenMark Diagnostics, Inc. (Carlsbad, CA, USA) have entered into a definitive merger agreement for Roche to fully acquire GenMark which provides molecular diagnostic tests that are designed to detect multiple pathogens from a single patient sample.
Read More
26 Jan 2021
Roche Renews Partnership with Sysmex to Deliver Hematology Testing Solutions
Under the new framework of a Global Business Partnership Agreement (GBP) signed between Roche (Basel, Switzerland) and Sysmex Corporation (Kobe, Japan), both the companies have renewed their commitment to their long standing Distribution, Sales and Service (DSS) agreement, allowing Roche to continue to distribute Sysmex hematology products, including instruments and reagents.
Read More
18 Oct 2018
Roche Launches Roche Healthcare Consulting
Roche (Basel, Switzerland) has launched Roche Healthcare Consulting, a specialized consulting service that aims to help leaders in laboratories, hospitals and other healthcare groups optimize their operational, clinical and financial performance.
Read More

Additional news

28 Sep 2022
Global Infectious Disease IVD Market Dominated by Molecular Diagnostics Technology
The global infectious disease in vitro diagnostics (IVD) market stood at USD 113.7 billion in 2021 and is expected to grow at a CAGR of -7.41% from 2022 to 2030 to hit around USD 56.89 billion by 2030, driven by the rising prevalence of infectious diseases, such as tuberculosis and COVID-19, and technological advancements.
Read More
27 Sep 2022
Mindray Showcases Hematology Innovations at ISLH 2022
Mindray (Shenzhen, China) showcased its hematology innovations and academic achievements to medical experts from Europe and around the world at the International Symposium on Technological Innovations in Laboratory Hematology (ISLH 2022) held between September 8-10 in Bologna, Italy.
Read More
23 Sep 2022
Parker Labs Partners with Tristel to Deliver Ultrasound Disinfectant for U.S. Market
Parker Laboratories Inc. (Fairfield, NJ, USA) has entered a commercial partnership with Tristel plc (Newmarket, UK) to manufacture and distribute the company's disinfectant foams for U.S. markets.
Read More
19 Sep 2022
Pluslife and FIND Set Collaborate to Empower LMICs with Next-Gen POC Molecular Testing in Women’s Healthcare
Guangzhou Pluslife Biotechnology (Pluslife, Guangzhou, China) and the Foundation for Innovative New Diagnostics (FIND, Geneva, Switzerland) have entered into a strategic collaboration to support low- and middle-income countries (LMICs) in the development of diagnostic tools for women’s healthcare by providing access to next generation point of care (POC) molecular testing technology.
Read More
19 Sep 2022
RSNA 2022 to Showcase Latest Technologies for Advancing Patient Care
The Radiological Society of North America’s (RSNA, Oak Brook, IL, USA) has announced Technical Exhibits highlights for their 108th Scientific Assembly and Annual Meeting (RSNA 2022) held in Chicago at McCormick Place, Nov. 27 – Dec. 1.
Read More
16 Sep 2022
International Hospital Federation Awards 2022 Finalists Announced
The International Hospital Federation (IHF; Geneva, Switzerland) has announced the finalists of the IHF Awards 2022 after scoring entries in seven categories.
Read More
16 Sep 2022
Intelerad Acquires Life Image to Create World’s Largest Medical Image Exchange Network
Intelerad Medical Systems (Raleigh, NC, USA), a leading global provider of enterprise imaging solutions, has acquired Life Image (Newton, MA, USA), one of the largest image exchange networks of curated clinical and imaging data, creating the largest medical image exchange network in the world and laying the groundwork for the elimination of costly CDs as the primary means of image transfer.
Read More
13 Sep 2022
Global Diagnostic Labs Market Driven by Increased POCT Testing and Smart Portable Devices
The global diagnostic labs market is projected grow at a CAGR of 8.3% from over USD 297 billion in 2021 to more than USD 514 billion by 2028, driven by the increasing prevalence of chronic diseases, growing use of POC diagnostics, and rising healthcare expenditures.
Read More
12 Sep 2022
ECR 2023 Now Set to Take Place from 1-5 March in Vienna
The European Society of Radiology (ESR, Vienna, Austria) has announced that the European Congress of Radiology (ECR) 2023 will now take place on March 1-5, 2023 in Vienna.
Read More
Copyright © 2000-2022 TradeMed.com. All rights reserved. | Terms And Conditions